Neoantigen-specific CD4+ tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients
Hall MS, et al.
Journal for ImmunoTherapy of Cancer
November 2023
Authors and Affiliates
MacLean S Hall 1,2, Jamie K Teer 3, Xiaoqing Yu 3, Holly Branthoover 1, Sebastian Snedal 1, Madeline Rodriguez-Valentin 1, Luz Nagle 1, Ellen Scott 1, Ben Schachner 1, Patrick Innamarato 1, Amy M Hall 1, Jamie Blauvelt 1, Carolyn J Rich 4, Allison D Richards 4, Jake Ceccarelli 5, T J Langer 5, Sean J Yoder 6, Matthew S Beatty 1, Cheryl A Cox 7, Jane L Messina 8, Daniel Abate-Daga 1, James J Mule 1, John E Mullinax 1,9, Amod A Sarnaik 1,4, Shari Pilon-Thomas 10;
1 Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
2 Cancer Biology PhD Program, University of South Florida, Tampa, Florida, USA.
3 Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
4 Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
5 Turnstone Biologics, Inc, San Diego, California, USA.
6 Molecular Genomics Core, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
7 Cell Therapies Core Facility, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
8 Department of Anatomic Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
9 Department of Sarcoma, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
10 Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA shari.pilon-thomas@moffitt.org.